SAV-PA) et la solution de BCIP/NBT prête à l'emploi proviennent de Sigma-Aldrich ,
Les anticorps sont développés chez la souris, 13A5) et anti-IL10 humaine (clone JES-9D7), les anticorps biotinylés anti-IL6 humaine (MQ2-39C3) et anti-IL10 humaine (JES3-12G8), ainsi que les protéines recombinantes IL6 et IL10 humaines ont été fournis par eBioscience ,
Omics-Based Molecular Target and Biomarker Identification, Methods Mol Biol Clifton NJ, vol.719, pp.547-71, 2011. ,
DOI : 10.1007/978-1-61779-027-0_26
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742302
Personalized Medicine in Breast Cancer: A Systematic Review, Journal of Breast Cancer, vol.15, issue.3, pp.265-72, 2012. ,
DOI : 10.4048/jbc.2012.15.3.265
Les données -Institut National Du cancer -Incidence et mortalité estimées des cancers en France métropolitaine en 2012 [Internet]. [consulté le 5 sept Disponbile en ligne: http://lesdonnees.e-cancer.fr/les-indicateurs/29-incidence-mortalite/38-ensemble- des-cancers/28-epidemiologie-des-cancers-en-france-metropolitaine-incidence/45- incidence-mortalite-estimees-cancers-france-metropolitaine-tous-sexes.html 7, Cancer Incidence and Mortality Worldwide: IARC CancerBase No, D. Global cancer statistics, pp.69-90, 2010. ,
The present and future burden of urinary bladder cancer in the world, World Journal of Urology, vol.102, issue.2, pp.289-93, 2009. ,
DOI : 10.1007/s00345-009-0383-3
The changing patterns of bladder cancer in Egypt over the past 26??years, Cancer Causes & Control, vol.28, issue.4, pp.421-430, 2008. ,
DOI : 10.1007/s10552-007-9104-7
Le système urinaire [Internet]. [consulté le 9 sept, Disponible en ligne, 2013. ,
Clinical Practice Guidelines Bladder Cancer Disponible en ligne, 2013. ,
Recommandations en Onco-Urologie 2010 : Tumeurs uroth??liales, Progr??s en Urologie, vol.20, pp.255-274, 2010. ,
DOI : 10.1016/S1166-7087(10)70043-9
Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials, European Urology, vol.49, issue.3, pp.466-465, 2006. ,
DOI : 10.1016/j.eururo.2005.12.031
Risk Tables for Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer [Internet], 2006. ,
Diagnosis and treatment of bladder cancer, Am Fam Physician, vol.80, issue.7, pp.717-740, 2009. ,
Critical Evaluation of Urinary Markers for Bladder Cancer Detection and Monitoring, Rev Urol, vol.10, issue.2, pp.120-155, 2008. ,
Biomarkers for detection and surveillance of bladder cancer, Canadian Urological Association Journal, vol.2, issue.3, pp.212-233, 2008. ,
DOI : 10.5489/cuaj.600
Cystoscopie en fluorescence pour les tumeurs superficielles de vessie : apport de l???hexaminol??vulinate (Hexvix??) et du diagnostic photodynamique, Progr??s en Urologie - FMC, vol.19, issue.1, pp.9-14, 2009. ,
DOI : 10.1016/S1761-676X(09)70028-8
Bladder cancer biomarkers and their role in surveillance and screening, International Journal of Urology, vol.26, issue.1, pp.23-30, 2009. ,
DOI : 10.1111/j.1442-2042.2008.02174.x
Patients??? perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison, BJU International, vol.66, issue.9, pp.1106-1116, 2008. ,
DOI : 10.1016/j.urology.2004.09.050
EAU Guidelines on Non???Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update, European Urology, vol.59, issue.6, pp.997-1008, 2011. ,
DOI : 10.1016/j.eururo.2011.03.017
2009 [consulté le 11 sept. 2013] Available from ,
Economic aspects of bladder cancer: what are the benefits and costs?, World Journal of Urology, vol.42, issue.Suppl 1, pp.295-300, 2009. ,
DOI : 10.1007/s00345-009-0395-z
Complement factor H or a related protein is a marker for transitional cell cancer of the bladder, Clin Cancer Res, vol.4, issue.10, pp.2511-2531, 1998. ,
Int??r??t des marqueurs urinaires dans le diagnostic et le suivi des tumeurs uroth??liales de vessie, Progr??s en Urologie, vol.17, issue.1, pp.23-34, 2007. ,
DOI : 10.1016/S1166-7087(07)92221-6
Complement Factor H as a Marker for Detection of Bladder Cancer, Clinical Chemistry, vol.51, issue.5, pp.856-63, 2005. ,
DOI : 10.1373/clinchem.2004.042192
Urinary Markers in Bladder Cancer, European Urology, vol.53, issue.5, pp.909-925, 2008. ,
DOI : 10.1016/j.eururo.2007.12.006
Detection of Bladder Cancer Using a Novel Nuclear Matrix Protein, BLCA-4, Clin Cancer Res, vol.6, issue.7, pp.2618-2643, 2000. ,
RETRACTED: Highly specific urine-based marker of bladder cancer, Urology, vol.66, issue.6, pp.1256-60, 2005. ,
DOI : 10.1016/j.urology.2005.07.010
Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine, International Journal of Cancer, vol.89, issue.6, pp.364-373, 2001. ,
DOI : 10.1002/1097-0215(20011120)95:6<364::AID-IJC1064>3.0.CO;2-V
Current and Emerging Bladder Cancer Urinary Biomarkers, The Scientific World JOURNAL, vol.11, pp.1103-1115, 2011. ,
DOI : 10.1100/tsw.2011.104
URL : http://doi.org/10.1100/tsw.2011.104
Real-Time Quantitative Telomeric Repeat Amplification Protocol Assay for the Detection of Telomerase Activity, Clin Chem, vol.47, issue.3, pp.519-543, 2001. ,
Tumor Markers in the Diagnosis of Primary Bladder Cancer. A Systematic Review, The Journal of Urology, vol.169, issue.6, pp.1975-82, 2003. ,
DOI : 10.1097/01.ju.0000067461.30468.6d
Urinary CYFRA 21.1 Is Not a Useful Marker for the Detection of Recurrences in the Follow-Up of Superficial Bladder Cancer, European Urology, vol.51, issue.5, pp.1267-74, 2007. ,
DOI : 10.1016/j.eururo.2006.12.019
URINARY HYALURONIC ACID AND HYALURONIDASE:, The Journal of Urology, vol.163, issue.1, pp.348-56, 2000. ,
DOI : 10.1097/00005392-200001000-00093
HYAL1 Hyaluronidase: A Molecular Determinant of Bladder Tumor Growth and Invasion, Cancer Research, vol.65, issue.6, p.2243, 2005. ,
DOI : 10.1158/0008-5472.CAN-04-2805
Survivin expression is associated with bladder cancer presence, stage, progression, and mortality, Cancer, vol.63, issue.33, pp.1106-1119, 2007. ,
DOI : 10.1002/cncr.22521
Evaluation of Survivin Reverse Transcriptase-Polymerase Chain Reaction for Noninvasive Detection of Bladder Cancer, The Journal of Urology, vol.175, issue.6, pp.2312-2318, 2006. ,
DOI : 10.1016/S0022-5347(06)00254-0
Urine Detection of Survivin is a Sensitive Marker for the Noninvasive Diagnosis of Bladder Cancer, The Journal of Urology, vol.171, issue.2, pp.626-656, 2004. ,
DOI : 10.1097/01.ju.0000107826.78479.90
How Are We Going to Discover New Cancer Biomarkers? A Proteomic Approach for Bladder Cancer, Clinical Chemistry, vol.50, issue.5, pp.793-798, 2004. ,
DOI : 10.1373/clinchem.2004.032177
The Path to Personalized Medicine, New England Journal of Medicine, vol.363, issue.4, 2010. ,
DOI : 10.1056/NEJMp1006304
Getting to personalized cancer medicine, Cancer, vol.110, issue.8, pp.1641-1644, 2007. ,
DOI : 10.1002/cncr.22966
Personalized Medicine: Marking a New Epoch in Cancer Patient Management, Molecular Cancer Research, vol.8, issue.9, pp.1175-87, 2010. ,
DOI : 10.1158/1541-7786.MCR-10-0264
Applications of protein microarrays for biomarker discovery, PROTEOMICS - CLINICAL APPLICATIONS, vol.1, issue.10-11, pp.10-111444, 2008. ,
DOI : 10.1002/prca.200800032
Proteomics Discovery of Disease Biomarkers. Biomark Insights, pp.325-358, 2008. ,
Putting the "Bio" back into Biomarkers: Orienting Proteomic Discovery toward Biology and away from the Measurement Platform, Clinical Chemistry, vol.54, issue.1, pp.3-5, 2008. ,
DOI : 10.1373/clinchem.2007.097659
Array Technology: Protein-Based Predictive Medicine and Drug Discovery Applications, Journal of Biomedicine and Biotechnology, vol.2003, issue.4, 2003. ,
DOI : 10.1155/S1110724303210020
URL : http://doi.org/10.1155/s1110724303210020
Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in Urine, The American Journal of Pathology, vol.158, issue.4, pp.1491-502, 2001. ,
DOI : 10.1016/S0002-9440(10)64100-4
Protein Microarrays for Personalized Medicine, Clinical Chemistry, vol.56, issue.3, pp.376-87, 2010. ,
DOI : 10.1373/clinchem.2009.137158
: Systems Biology, Annual Review of Genomics and Human Genetics, vol.2, issue.1, pp.343-72, 2001. ,
DOI : 10.1146/annurev.genom.2.1.343
Reductionism and complexity in molecular biology, EMBO reports, vol.23, issue.11, pp.1016-1036, 2004. ,
DOI : 10.1046/j.1432-1327.2001.02167.x
Strategies for discovering novel cancer biomarkers through utilization of emerging technologies, Nature Clinical Practice Oncology, vol.18, issue.10, 2008. ,
DOI : 10.1038/ncponc1187
Biomarkers for Cancer Risk, Early Detection, and Prognosis: The Validation Conundrum, Cancer Epidemiology Biomarkers & Prevention, vol.16, issue.10, 2007. ,
DOI : 10.1158/1055-9965.EPI-07-2619
Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers, JNCI Journal of the National Cancer Institute, vol.88, issue.20, pp.1456-66, 1996. ,
DOI : 10.1093/jnci/88.20.1456
Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications, Amer. Assoc. for Clinical Chemistry, 2002. ,
Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials, Journal of Clinical Oncology, vol.23, issue.9, pp.2020-2027, 2005. ,
DOI : 10.1200/JCO.2005.01.112
Randomized Clinical Trials With Biomarkers: Design Issues, JNCI Journal of the National Cancer Institute, vol.102, issue.3, pp.152-60, 2010. ,
DOI : 10.1093/jnci/djp477
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology, J Natl Compr Cancer Netw JNCCN, vol.9, pp.1-32, 2011. ,
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers, JNCI Journal of the National Cancer Institute, vol.101, issue.21, pp.1446-52, 2009. ,
DOI : 10.1093/jnci/djp335
Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.10, pp.1626-1660, 2008. ,
DOI : 10.1200/JCO.2007.14.7116
Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer, New England Journal of Medicine, vol.359, issue.17, pp.1757-65, 2008. ,
DOI : 10.1056/NEJMoa0804385
Protein microarrays for diagnostic assays, Analytical and Bioanalytical Chemistry, vol.20, issue.5, pp.1407-1423, 2009. ,
DOI : 10.1007/s00216-008-2379-z
Antibody-Based Protein Multiplex Platforms: Technical and Operational Challenges, Clinical Chemistry, vol.56, issue.2, pp.186-93, 2010. ,
DOI : 10.1373/clinchem.2009.127514
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901849
Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell, pp.317-342, 2003. ,
Protein chip technology, Current Opinion in Chemical Biology, vol.7, issue.1, pp.55-63, 2003. ,
DOI : 10.1016/S1367-5931(02)00005-4
Nouvelle approche globale en protéomique : les biopuces à protéines ,
Multiplex approaches in protein microarray technology, Expert Review of Proteomics, vol.2, issue.4, pp.499-510, 2005. ,
DOI : 10.1586/14789450.2.4.499
Microarrays to characterize protein interactions on a whole-proteome scale, PROTEOMICS, vol.3, issue.11, pp.2190-2199, 2003. ,
DOI : 10.1002/pmic.200300610
Analyzing antibody specificity with whole proteome microarrays, Nature Biotechnology, vol.21, issue.12, 2003. ,
DOI : 10.1038/nbt910
Protein microarrays: Molecular profiling technologies for clinical specimens, PROTEOMICS, vol.3, issue.11, pp.2091-100, 2003. ,
DOI : 10.1002/pmic.200300592
Antibody Arrays in Cancer Research, Molecular & Cellular Proteomics, vol.4, issue.4, pp.377-83, 2005. ,
DOI : 10.1074/mcp.M500010-MCP200
Protein microarrays and proteomics, Nature Genetics, vol.32, issue.Supp, pp.526-558, 2002. ,
DOI : 10.1038/ng1037
Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma, Molecular & Cellular Proteomics, vol.4, issue.4, pp.346-55, 2005. ,
DOI : 10.1074/mcp.T500003-MCP200
System can detect 9600 proteins or DNA molecules simultaneously, 2008. ,
AimPlex Multiplex Immunoassay for Flow -How It Works ,
Protein and antibody microarray technology, Journal of Chromatography B, vol.797, issue.1-2, pp.229-269, 2003. ,
DOI : 10.1016/j.jchromb.2003.08.034
Methods and applications of antibody microarrays in cancer research, PROTEOMICS, vol.3, issue.11, pp.2116-2138, 2003. ,
DOI : 10.1002/pmic.200300595
Progress in protein and antibody microarray technology. Drug Discov Today, Apr, vol.110, issue.7, pp.503-514, 2005. ,
Immunoanalyse: De la théorie aux critères de choix en biologie clinique, EDP Sciences, 2012. ,
Multiplexed protein measurement: technologies and applications of protein and antibody arrays, Nature Reviews Drug Discovery, vol.4, issue.4, pp.310-330, 2006. ,
DOI : 10.1007/s11095-005-2495-9
Multiplexed protein profiling on microarrays by rolling-circle amplification, Nature Biotechnology, vol.20, issue.4, 2002. ,
DOI : 10.1038/nbt0402-359
Immunoassays with rolling circle DNA amplification: A versatile platform for ultrasensitive antigen detection, Proceedings of the National Academy of Sciences, vol.97, issue.18, pp.10113-10122, 2000. ,
DOI : 10.1073/pnas.170237197
A chip-based miniaturized format for protein-expression profiling: The exploitation of comprehensively produced antibodies, ELECTROPHORESIS, vol.85, issue.18, pp.3676-83, 2006. ,
DOI : 10.1002/elps.200500821
Label-free detection methods for protein microarrays, PROTEOMICS, vol.21, issue.20, pp.5493-503, 2006. ,
DOI : 10.1002/pmic.200600216
A novel approach to protein expression profiling using antibody microarrays combined with surface plasmon resonance technology, PROTEOMICS, vol.1, issue.9, pp.2396-401, 2005. ,
DOI : 10.1002/pmic.200401171
Global Analysis of Protein Activities Using Proteome Chips, Science, vol.293, issue.5537, pp.2101-2106, 2001. ,
DOI : 10.1126/science.1062191
Peptide chips for the quantitative evaluation of protein kinase activity, Nature Biotechnology, vol.20, issue.3, pp.270-274, 2002. ,
DOI : 10.1038/nbt0302-270
Multiplexed Cell Signaling Analysis of Human Breast Cancer Applications for Personalized Therapy, Journal of Proteome Research, vol.7, issue.4, pp.1508-1525, 2008. ,
DOI : 10.1021/pr7008127
Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment, The FASEB Journal ,
DOI : 10.1096/fj.01-0711fje
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Clinical Practice: Quality Requirements, Clinical Chemistry, vol.54, issue.8, pp.1-10, 2008. ,
DOI : 10.1373/clinchem.2007.094144
Measurement and Quality Control Issues in Multiplex Protein Assays: A Case Study, Clinical Chemistry, vol.55, issue.6, pp.1092-1101, 2009. ,
DOI : 10.1373/clinchem.2008.120717
Quality Control and Protein Microarrays, Clinical Chemistry, vol.55, issue.6, 2009. ,
DOI : 10.1373/clinchem.2009.126557
Optimized Normalization for Antibody Microarrays and Application to Serum-Protein Profiling, Molecular & Cellular Proteomics, vol.4, issue.6, pp.773-84, 2005. ,
DOI : 10.1074/mcp.M400180-MCP200
Executive summary: the MicroArray Quality Control (MAQC) project: toward consensus on Best Practices " for the generation, analysis, and application of microarray data in the discovery, development, and review of FDA-regulated products, 2006. ,
IL-6 Expression Regulates Tumorigenicity and Correlates with Prognosis in Bladder Cancer, PLoS One, 2013. ,
IL-8 as a urinary biomarker for the detection of bladder cancer, BMC Urology, vol.13, issue.1, p.12, 2012. ,
DOI : 10.1016/S0022-5347(05)65290-1
Role of IL-10 in Urinary Bladder Carcinoma and Bacillus Calmette-Guerin Immunotherapy, Am J Immunol, vol.8, issue.1, pp.1-9, 2012. ,
Adhesive microarrays for multipurpose diagnostic tools. Lab Chip, pp.3006-3016, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00631239
Miniaturized Protein Microarray with Internal Calibration as Point-of-Care Device for Diagnosis of Neonatal Sepsis. Sensors, Feb, vol.312, issue.2, pp.1494-508, 2012. ,
Concentration and preservation of very low abundance biomarkers in urine, such as human growth hormone (hGH), by Cibacron Blue F3G-A loaded hydrogel particles, Nano Research, vol.62, issue.Suppl1, pp.502-520, 2008. ,
DOI : 10.1007/s12274-008-8054-z
Preanalytical guidelines for clinical proteomics investigation of biological fluids, Ann Biol Clin, vol.67, issue.6, pp.629-668, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00444355